| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910678471803321 |
|
|
Autore |
Calkins Tim |
|
|
Titolo |
Amgen : launching Repatha / / Tim Calkins, Mike Harris |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
London : , : Kellogg School of Management, , 2017 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource : illustrations |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Heart - Diseases - Treatment - United States |
Hypercholesteremia |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Originally published in Calkins, T., & Harris, M. (2017). Amgen: Launching Repatha. 5-416-759. Evanston, IL: Kellogg School of Management at Northwestern University. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast. |
|
|
|
|
|
|
|
| |